Reminder: Charts are updated every Sunday evening for the next week!
Catalyst Swing Names (1-4 week holds) that I am watching:
VtV Therapeutics (VTVT)
Catalyst Dates: Phase 2 Type 1 diabetes data due in June
Buy Zone: $1.25 to $1.50
Profit Zone: $1.90 or higher
Stop Zone: $1.10 or below
Pieris Pharmaceuticals (PIRS)
Catalyst Dates: Phase 1 data May 22nd
Buy Zone: $3.00 to $3.20
Profit Zone: $3.75 or higher
Stop Zone: $2.90 or below
Aduro (ADRO)
Catalyst Dates: Phase 1b and Phase 1/2 data due at ASCO June 2 and 3
Buy Zone: $3.75 to $4.00
Profit Zone: $4.90 or higher
Stop Zone: $3.50 or below
Sunesis Pharmaceuticals (SNSS)
Catalyst Dates: Phase 1/2 update due between June 13-16
Buy Zone: $1.40 to $1.55
Profit Zone: $1.90 or higher
Stop Zone: $1.25 or below
Palatin Technologies (PTN)
Catalyst Dates: FDA Approval Date of June 23rd for Female Sexual Dysfunction
Buy Zone: $1.05 to $1.15
Profit Zone: $1.40 or higher
Stop Zone: $1.00 or below
Marinus Pharmaceuticals (MRNS)
Catalyst Dates: Two Phase 2 data sets due in first half (likely June, but no set date)
Buy Zone: $4.20 to $4.50
Profit Zone: $5.20 or higher
Stop Zone: $4.10 or below
Sesen Bio (SESN)
Catalyst Dates: Phase 3 data update May 13th
Buy Zone: $.95 to $1.05
Profit Zone: $1.30 or higher
Stop Zone: $.90 or below
Sierra Oncology (SRRA)
Catalyst Dates: Phase 1/2 cancer data update likely due out at ASCO in June
Buy Zone: $1.30 to $1.50
Profit Zone: $1.85 or higher
Stop Zone: $1.10 or below
Achillion Pharmaceuticals (ACHN)
Catalyst Dates: Phase 2 Interim data May 17th
Buy Zone: $2.75 to $3.00
Profit Zone: $3.50 or higher
Stop Zone: $2.55 or below
Ovid Therapeutics (OVID)
Catalyst Dates: Phase 3 data due May 3
Buy Zone: $1.80 to $2.00
Profit Zone: $2.40 or higher
Stop Zone: $1.60 or below
Achieve Life Sciences (ACHV)
Catalyst Dates: Phase 2b data due out mid 2019. Likely May-June
Buy Zone: $3.80 to $4.20
Profit Zone: $5.00 or higher
Stop Zone: $3.25 or below
[Ed.note: Kyle Dennis runs BiotechBreakouts.com. He is an event-based trader, who prefers low-priced and small-cap biotech stocks.